Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia

Pharmacogenetics and Genomics

Volumn 16, Issue 3, 2006, Pages 151-157

  Liou, Ying Jay ^a,b   Lai, I Ching ^b   Lin, Ming Wei ^c   Bai, Ya Mei ^b,d   Lin, Chao Cheng ^b   Liao, Ding Lieh ^e   Chen, Jen Yeu ^b   Lin, Chih Yuan ^b   Wang, Ying Chieh ^b,f  

^a Institute of Clinical Medicine   (Taiwan)

^b YULI VETERANS HOSPITAL   (Taiwan)

^c TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^d NATIONAL YANG MING UNIVERSITY   (Taiwan)

^e Pali Psychiatric Hospital   (Taiwan)

^f TZU CHI UNIVERSITY   (Taiwan)

Author keywords

Endothelial nitric oxide synthase; NOS3; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

NEUROLEPTIC AGENT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; PATHOGENESIS; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; VARIABLE NUMBER OF TANDEM REPEAT;

ADULT; ALLELES; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DYSKINESIA, DRUG-INDUCED; HAPLOTYPES; HUMANS; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; ODDS RATIO; PHARMACOGENETICS; PROMOTER REGIONS (GENETICS); SCHIZOPHRENIA; VARIATION (GENETICS);

EID: 33644607597     PISSN: 17446872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Lohr JB, Kuczenski R, Nioulescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17:47-62.
2. Waddington JL, Cross AJ, Gamble SJ, Bourne RC. Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science 1983; 220:530-532.
3. Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann N Y Acad Sci 1989; 570:176-185.
4. Lohr JB, Caligiuri MP. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia. J Clin Psychiatry 1996; 57:167-173.
5. Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001; 58:1049-1052.
6. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996; 19:1-17.
7. Lipton SA, Choi YB, Pan ZH, Lei SZ, Chen HS, Sucher NJ, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds. Nature 1993; 364:626-632.
8. Wink DA, Vodovotz Y, Grisham MB, DeGraff W, Cook JC, Pacelli R, et al. Antioxidant effects of nitric oxide. Methods Enzymol 1999; 301:413-424.
9. Sandor NT, Brassai A, Puskas A, Lendvai B. Role of nitric oxide in modulating neurotransmitter release from rat striatum. Brain Res Bull 1995; 36:483-486.
10. Araki T, Mizutani H, Matsubara M, Imai Y, Mizugaki M, Itoyama Y. Nitric oxide synthase inhibitors cause motor deficits in mice. Eur Neuropsychopharmacol 2001; 11:125-133.
11. Ortiz PA, Garvin JL Trafficking and activation of eNOS in epithelial cells. Acta Physiol Scand 2003; 179:107-114.
12. Karatinos J, Rosse RB, Deutsch SI. The nitric oxide pathway: potential implications for treatment of neuropsychiatric disorders. Clin Neuropharmacol 1995; 18:482-499.
13. Nel A, Harvey BH. Haloperidol-induced dyskinesia is associated with striatal NO synthase suppression: reversal with olanzapine. Behav Pharmacol 2003; 14:251-255.
14. Naidu PS, Kulkarni SK. Excitatory mechanisms in neuroleptic-induced vacuous chewing movements (VCMs): possible involvement of calcium and nitric oxide. Behav Pharmacol 2001; 12:209-216.
15. Shinkai T, Ohmori O, Matsumoto C, Hori H, Kennedy JL, Nakamura J. Genetic association analysis of neuronal nitric oxide synthase gene polymorphism with tardive dyskinesia. Neuromolecular Med 2004; 5:163-170.
16. Wang YC, Liou YJ, Liao DL, Bai YM, Lin CC, Yu SC, et al. Association analysis of a neural nitric oxide synthase gene polymorphism and antipsychotics-induced tardive dyskinesia in Chinese schizophrenic patients. J Neural Transm 2004; 111:623-629.
17. Calabrese V, Bates TE, Stella AM. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role of oxidant/antioxidant balance. Neurochem Res 2000; 25:1315-1341.
18. Park CS, Krishna G, Ahn MS, Kang JH, Chung WG, Kim DJ, et al. Differential and constitutive expression of neuronal, inducible, and endothelial nitric oxide synthase mRNAs and proteins in pathologically normal human tissues. Nitric Oxide 2000; 4:459-471.
19. Buchholzer ML, Klein J. NMDA-induced acetylcholine release in mouse striatum: role of NO synthase isoforms. J Neurochem 2002; 82: 1558-1560.
20. Sohn YK, Ganju N, Bloch KD, Wands JR, de la Monte SM. Neuritic sprouting with aberrant expression of the nitric oxide synthase III gene in neurodegenerative diseases. J Neurol Sci 1999; 162:133-151.
21. Sachdev PS. The current status of tardive dyskinesia. Aust N Z J Psychiatry 2000; 34:355-369.
22. Kane JM, Aguglia E, Altamura AC, Ayuso Gutierrez JL, Brunello N, Fleischhacker WW, et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena Italy. Eur Neuropsychopharmacol 1998; 8:55-66.
23. Practice guideline for the treatment of patients with schizophrenia. American Psychiatric Association. Am J Psychiatry 1997; 154:1-63.
24. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics: I. Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989; 4:95-104.
25. Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, Liao DL, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49:167-173.
26. Munetz MR, Benjamin S. How to examine patients using the Abnormal Involuntary Movement Scale. Hosp. Community Psychiatry 1988; 39:1172-1177.
27. Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ. Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2001; 44:95-98.
28. Lai IC, Wang YC, Lin CC, Bai YM, Liao DL, Yu SC, et al. Negative association between Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. J Neural Transm 2005; 112:1107-1113.
29. Chen JY, Bai YM, Pyng LY, Lin CC. Risperidone for tardive dyskinesia. Am J Psychiatry 2001; 158:1931-1932.
30. Bai YM, Yu SC, Chen JY, Lin CY, Chou P, Lin CC. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. Int Clin Psychopharmacol 2005; 20:79-85.
31. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized double-blind placebo-controlled study. J Clin Psychiatry 2003; 64:1342-1348.
32. Liou YJ, Liao DL, Chen JY, Wang YC, Lin CC, Bai YM, et al. Association analysis of the dopamine D3 receptor gene ser9gly and brain-derived neurotrophic factor gene val66met polymorphisms with antipsychotic-induced persistent tardive dyskinesia and clinical expression in Chinese schizophrenic patients. Neuromolecular Med 2004; 5:243-251.
33. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487.
34. Lahiri DK, Nurnberger JI Jr. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19:5444.
35. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat Med 1996; 2:41-45.
36. Freedman BI, Yu H, Anderson PJ, Roh BH, Rich SS, Bowden DW. Genetic analysis of nitric oxide and endothelin in end-stage renal disease. Nephrol Dial Transplant 2000; 15:1794-1800.
37. Dupont WD, Plummer WD Jr. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998; 19:589-601.
38. Zhao JH. 2LD, GENECOUNTING and HAP: Computer programs for linkage disequilibrium analysis. Bioinformatics 2004; 20:1325-1326.
39. Zhao JH, Lissarrague S, Essioux L, Sham PC. GENECOUNTING: haplotype analysis with missing genotypes. Bioinformatics 2002; 18:1694-1695.
40. TanusSantos JE, Desai M, Flockhart DA. Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics 2001; 11:719-725.
41. Malhotra AK, Murphy GM Jr, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161:780-796.
42. Athanasiou MC, Malhotra AK, Xu C, Stephens JC. Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet 2002; 12:89-96.
43. Wang J, Dudley D, Wang XL. Haplotype-specific effects on endothelial NO synthase promoter efficiency: modifiable by cigarette smoking. Arterioscler Thromb Vasc Biol 2002; 22:e1-e4.
44. Nakayama M, Yasue H, Yoshimura M, Shimasaki Y, Kugiyama K, Ogawa H, et al. T-786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999; 99:2864-2870.
45. Metzger IF, Souza-Costa DC, Marroni AS, Nagassaki S, Desta Z, Flockhart DA, et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. Pharmacogenet Genomics 2005; 15:565-570.
46. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ, Sessa WC. Acidic hydrolysis as a mechanism for the cleavage of the Glu(298) → Asp variant of human endothelial nitric-oxide synthase. J Biol Chem 2001; 276:26674-26679.
47. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97:2832-2835.
48. Cooke JP. Role of nitric oxide in progression and regression of atherosclerosis. West J Med 1996; 164:419-424.
49. Sofowora G, Dishy V, Xie HG, Imamura H, Nishimi Y, Morales CR, et al. In-vivo effects of Glu298Asp endothelial nitric oxide synthase polymorphism. Pharmacogenetics 2001; 11:809-814.
50. McDonald DM, Alp NJ, Channon KM. Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 2004; 14:831-839.
51. Stephens JC, Schneider JA, Tanguay DA, Choi J, Acharya T, Stanley SE, et al. Haplotype variation and linkage disequilibrium in 313 human genes. Science 2001; 293:489-493.
52. Muller DJ, Shinkai T, De Luca V, Kennedy JL Clinical implications of pharmacogenomics for tardive dyskinesia. Pharmacogenomics J 2004; 4:77-87.
53. Ohmori O, Shinkai T, Hori H, Matsumoto C, Nakamura J. A perspective on molecular genetic studies of tardive dyskinesia: one clue for individualized antipsychotic drug therapy. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:581-586.
54. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin Psychiatry 2000; 61 (Suppl 3):16-21.